explore -WSS

explore

author：comprehensive 2025-09-03 15:17:59 - browse：81

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Senate HELP committee spars over health care workforce policies

Wikipedia

WSS

Senators: Long

Sudafed saga points to U.S. issues with evaluating older drugs

FDA seeks to regulate lab

STAT Virtual Event: Putting AI to the Test

How one patient went off dialysis — and others can too

After a drawn out lobbying fight, ARPA

hotspot

explore

explore

Apple is now the first public company to be valued at $3 trillion

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Medicare proposal to cover medical devices draws a mixed reaction

Data show record exodus of life scientists from academia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Paxlovid should be available without a positive Covid test

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Address the ethical violations that led to 'Three Identical Strangers'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug for rare kidney disease narrowly misses mark in clinical trial

leisure time

Ionis has late

It's been 20 years since Dolly the sheep. Where's my clone?

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Ukraine and a new approach to mental health in war

How AI helped researchers track recovery from depression

leisure time

Wikipedia

entertainment

focus